Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC. Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered. Silke Gillessen, MD, PhD joins The Uromigos to discuss the genitourinary oncology highlights of ASCO 2023. The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD. Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial. Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC. Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT. Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC. Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023. We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for. Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer. Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain. Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer. Nazli Dizman covers an update on the CBM588 probiotic strain and its phase II trial. Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more. Robert Jones, MD, talks about the hypothesis for ATLANTIS, its specific trial results, and more. Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results. Silke Gillessen gives a safety update from this EORTC study focusing on fractures. Chris Sweeney and Silke Gillessen give their opinion of recent data on radionuclides therapy in prostate cancer. Dr. Kosj Yamoah of Moffitt Cancer Center describes the work he presented at ASCO 2021.